EMA Guideline on Manufacture of the Finished Dosage Form

The purpose of this guidance is to provide clarification on the type and level of information to be included in the CTD Module 3. This includes information about critical steps and intermediates and provides a link between the pharmaceutical development, the proposed control strategy and process validation. And this guideline also addresses aspects of outsourcing and new manufacturing practices.

Click to Open Official Publication

Download Resource